The following trials provide information to treat various types of gastrointestinal diseases, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse UPPER GI SYMPTOMS IN PATIENTS RECEIVING ACETYLSALICYLIC ACID/NSAIDS - NSAIDS Wave 2
- collapse Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients (Preedom)
- collapse Adherence to Gastro-Protection in Non-Steroidal Anti-Inflammatory Drug (NSAID) Using Patients
- collapse European Survey of Non-Variceal Upper Gastro Intestinal Bleeding (NVUGIB)
- collapse Epidemiological survey to describe impact of reflux disease on everyday life in GERD patients before and after 4 weeks treatment
- collapse A comparative study on 40 mg H 199/18 and 40 mg omeprazole with regard to effect on 24-hour intragastric pH in patients with symptomatic gastroesophageal reflux disease
- collapse An epidemiological, observational study to describe symptom control and impact on daily life of GERD in patients with erosive gastroesophageal reflux disease
- collapse Supportive Test for Acid Related Symptoms(STARSI) with esomeprazole and a following 7-week, double-blind, randomized, placebo controlled treatment period in patients with upper gastrointestinal symptoms and with normal findings at esophagogastroduodenoscopyl
- collapse Efficacy of esomeprazole 40mg q.d. versus placebo and 20mg q.d. versus placebo in treatment for relief of upper gastrointestinal symptoms associated with continuous use of NSAIDS including COX-2 selective NSAIDS.
- collapse A multicenter, double-blind study to evaluate the safety and therapeutic efficacy of omeprazole 20 mg once daily or 10 mg once daily as compared to placebo during 12-24 months maintenance treatment of patients with duodenal ulcer healed following 4 weeks of omeprazole 20 mg once daily.
